Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.

ABSTRACT:

Background

Adjuvant tegafur-gimeracil-oteracil (S-1) is commonly used for gastric cancer in Asia, and tegafur-uracil (UFT) is another oral fluoropyrimidine when S-1 is unavailable. The real-world data of adjuvant UFT has less been investigated.

Methods

Patients with pathological stage II-IIIB (except T1) gastric cancer receiving adjuvant UFT or S-1 monotherapy after D2 gastrectomy were included. Usage of UFT or S-1 was based on reimbursement policy of the Taiwanese healthcare system. The characteristics, chemotherapy completion rates, and 5-year recurrence-free survival (RFS) and overall survival (OS), were compared between these two groups.

Results

From 2005 to 2016, 86 eligible patients were included. Most tumor characteristics were similar between the UFT group (n

SUBMITTER: Yen HH 

PROVIDER: S-EPMC8053033 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature